LY2812223: Clinical Trials

1 trial of LY2812223, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow LY2812223: new trials by email Literature Review of LY2812223 trials Research Report on LY2812223

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
MP-101, Placebo - Psychosis, Dementia
Phase 2TerminatedMediti Pharma Inc.812017-05-042021-04-01

Conditions studied

Aggression (1)  ·  Alzheimer Disease (1)  ·  Dementia (1)  ·  Psychomotor Agitation (1)  ·  Psychotic Disorders (1)

Sponsors

Mediti Pharma Inc. (1)

Countries

Canada (1)  ·  United States (1)